Jennifer Clune, MD
Pulmonary Disease · Dayton, OHNPI 1265589113
Payments from drug & device makers
Across 255 payments — averaging $50.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$7K
- AstraZeneca$1K
- Chiesi USA, Inc.$1K
- GSK$927
- Intuitive Surgical$676
- Johnson & Johnson$298
- plus $2K from 25 others
What the payments were for
- Speaking & faculty fees$6,69056%
- Travel & lodging$8467%
- Food & beverage$4,44537%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 31 | $7,205 |
| AstraZeneca | 46 | $1,229 |
| Chiesi USA, Inc. | 1 | $1,000 |
| GSK | 81 | $927 |
| Intuitive Surgical | 5 | $676 |
| Johnson & Johnson | 2 | $298 |
| Mylan Specialty L.p. | 18 | $248 |
| Sanofi | 8 | $143 |
| Grifols USA, LLC | 8 | $134 |
| Genentech USA, Inc. | 5 | $121 |
| Sunovion Pharmaceuticals Inc. | 7 | $111 |
| United Therapeutics Corporation | 2 | $100 |
| Pulmonx Corporation | 3 | $94 |
| Inspire Medical Systems, Inc. | 2 | $92 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $88 |
| Regeneron Healthcare Solutions, Inc. | 5 | $81 |
| Insmed, Inc. | 3 | $74 |
| Baxter Healthcare | 3 | $46 |
| Inogen, Inc. | 2 | $43 |
| Advanced Respiratory, Inc | 2 | $36 |
| Philips North America LLC | 2 | $33 |
| Bayer | 2 | $31 |
| Actelion Pharmaceuticals US, Inc. | 2 | $30 |
| Axsome Therapeutics, Inc. | 2 | $28 |
| Jazz Pharmaceuticals Inc. | 1 | $25 |
| Amgen | 1 | $24 |
| Electromed, Inc. | 2 | $22 |
| Merck | 1 | $19 |
| Lilly USA, LLC | 1 | $16 |
| Pfizer | 1 | $15 |
| Optinose US, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,000 in reported general payments places this provider in the 75th percentile of 571 pulmonary disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 409 | $330,267 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 13 | $178,867 |
| AdempasRiociguat | 12 | $170,157 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 139 | $98,546 |
| Dupixent SyringeDupilumab | 19 | $84,702 |
| Breo ElliptaFluticasone/Vilanterol | 162 | $83,472 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 84 | $56,946 |
| XolairOmalizumab | 14 | $55,165 |
| Spiriva RespimatTiotropium Bromide | 61 | $46,210 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 75 | $38,162 |
| DuleraMometasone/Formoterol | 44 | $17,645 |
| EliquisApixaban | 15 | $17,081 |
| SymbicortBudesonide/Formoterol Fumarate | 46 | $15,037 |
| Arnuity ElliptaFluticasone Furoate | 31 | $9,988 |
| Advair HfaFluticasone Propion/Salmeterol | 26 | $9,178 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $927 | $461,888677 claims |
| Grifols USA, LLCProlastin C | $134 | $178,86713 claims |
| BayerAdempas | $31 | $170,15712 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $1,229 | $119,103198 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $7,205 | $103,156145 claims |
| MerckDulera | $19 | $17,64544 claims |
| PfizerEliquis | $15 | $17,08115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 571 pulmonary disease providers in Ohio.
Other pulmonary disease in Dayton
- Thomas YungerDayton$401K
- Daniel PearsonDayton$61K
- Bruce CorserCincinnati$8.2M
- Edward CordascoColumbus$8M
- Kristin HighlandCleveland$3.2M
- Brian ZenoColumbus$2.9M
- Jean ElwingCincinnati$2.4M
- Roy St JohnColumbus$1.9M
- Nishant GuptaCincinnati$1.5M
- Robert BaughmanCincinnati$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.